Ekf Diagnostics Share Price (EKF)

Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  1.00 1.45% 70.00 470,290 16:35:07
Bid Price Offer Price High Price Low Price Open Price
69.00 71.00 71.00 69.00 69.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 44.92 5.52 0.81 86.4 318
Last Trade Time Trade Type Trade Size Trade Price Currency
16:46:57 O 55,000 70.25 GBX
Related Shares
Smith & Nephew (SN.), Convatec (CTEC), Widecells (WDC), Salvarx (SALV)

Ekf Diagnostics (EKF) Latest News

Ekf Diagnostics News

Date Time Source Headline
03/3/202107:00UKREGEKF Diagnostics Holdings PLC Notice of Results
19/2/202116:36UKREGEKF Diagnostics Holdings PLC Price Monitoring Extension
22/1/202116:41UKREGEKF Diagnostics Holdings PLC Second Price Monitoring Extn
22/1/202116:36UKREGEKF Diagnostics Holdings PLC Price Monitoring Extension
12/1/202111:47ALNCIN BRIEF: Payout Eyed At EKF On Covid Sample Collection Device Demand
12/1/202107:00UKREGEKF Diagnostics Holdings PLC Trading Update
05/1/202115:37UKREGEKF Diagnostics Holdings PLC Holding(s) in Company
30/12/202017:56UKREGEKF Diagnostics Holdings PLC Holding(s) in Company
14/12/202007:00UKREGEKF Diagnostics Holdings PLC Approval of dividend in specie
10/12/202013:09UKREGEKF Diagnostics Holdings PLC Result of General Meeting
More Ekf Diagnostics News
Ekf Diagnostics Investors    Ekf Diagnostics Takeover Rumours

Ekf Diagnostics (EKF) Discussions and Chat

Ekf Diagnostics Forums and Chat

Date Time Title Posts
05/3/202122:17EKF Diagnostics for income and growth - A healthy, reliable combination!1,581
24/9/202021:56EKF Diagnostics - Growth by acquisition, expertise and special relationships1,376
27/7/201105:35EKF Diagnostics – Growth by acquisition, expert knowledge and special relationsh7
25/7/201113:22EKF Diagnostics209
13/7/201020:15EFK DIAGNOSTICS6

Add a New Thread

Ekf Diagnostics (EKF) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-03-05 18:05:3570.2555,00038,637.50O
2021-03-05 17:15:0073.00158,722115,867.06O
2021-03-05 16:46:5870.2152,50236,861.65O
2021-03-05 16:35:0770.007,7605,432.00UT
2021-03-05 16:29:5469.502718.77AT
View all Ekf Diagnostics trades in real-time

Ekf Diagnostics (EKF) Top Chat Posts

DateSubject
05/3/2021
08:20		Ekf Diagnostics Daily Update: Ekf Diagnostics Holdings Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker EKF. The last closing price for Ekf Diagnostics was 69p.
Ekf Diagnostics Holdings Plc has a 4 week average price of 66p and a 12 week average price of 59p.
The 1 year high share price is 80.50p while the 1 year low share price is currently 16.93p.
There are currently 454,993,227 shares in issue and the average daily traded volume is 202,814 shares. The market capitalisation of Ekf Diagnostics Holdings Plc is £318,495,258.90.
Read Full Thread
Reply
03/3/2021
11:47		rivaldo: I'd expect a nice run-up in the share price prior to the results on 30th March - and hopefully afterwards! Particularly given the year end trading statement: Https://www.investegate.co.uk/ekf-diagnostics-hldg--ekf-/rns/trading-update/202101120700063139L/ " Full year performance expected to be comfortably ahead of upgraded market consensus Q1 2021 performance to materially exceed management expectations EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, confirms that continued strong trading will result in the performance for the year ending 31 December 2020 being comfortably ahead of already upgraded market expectations..... ....With continued strong performance in the core business and a number of indicative orders for PrimeStore MTM for the first quarter 2021 that are likely to be realised, the Board is confident that performance for the first quarter of 2021 will be materially ahead of current management expectations, and the first quarter of 2020."
Read Full Thread
Follow
Reply
03/3/2021
07:36		wan: An interesting comparison - Last years Notice of FY Results announcement contained the following description - About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com ) EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers. hTTps://uk.advfn.com/stock-market/london/ekf-diagnostics-EKF/share-news/EKF-Diagnostics-Holdings-PLC-Notice-of-Results/81906145 Todays announcement contains the following description - About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com ) EKF Diagnostics Holdings plc specialises in the development, production and worldwide distribution of point-of-care analyzers and clinical chemistry reagents for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF is also a bulk manufacturer of enzymes and has custom manufacturing facilities in the USA for a variety of life science products. In 2020, EKF developed a range of COVID-19 testing products including PrimeStore MTM, an FDA-approved and CE marked sample containment device that allows the safe handling, transportation and analysis of test swabs and samples, which it manufactures under licence, and COVID-SeroKlir, a leading ELISA-based antibody test from Kantaro Biosciences that provides a precise measurement of COVID-19 IgG antibodies. hTTps://uk.advfn.com/stock-market/london/ekf-diagnostics-EKF/share-news/EKF-Diagnostics-Holdings-PLC-Notice-of-Results/84481970 In my opinion only, this further supports my view that PrimeStore products will become core EKF products i.e. in constant use for the foreseeable (as perhaps exemplified by SBI's expansion in the US), and in that I also include country surveillance and preparedness.
Read Full Thread
Follow
Reply
18/2/2021
09:13		mirandaj: As the share price of MyHealthChecked continues to increase I wonder how many collection devices have been ordered since initial supply. From December 2nd 2020 The MyHealthChecked™ COVID-19 testing service will use the Clarigene® SARS-CoV-2 test supplied by Yourgene Health plc (AIM: YGEN) and the PrimeStore® MTM sample collection device supplied by EKF Diagnostic Holdings plc (AIM: EKF). The MyHealthChecked™ testing service allows samples to be quickly and conveniently taken at home using simple nasal collection swabs which are then sent via free postage for processing using established laboratory-based DNA and RNA detection methods. In addition, initial purchase orders (of £16,500) have been placed with EKF Diagnostic Holdings plc ("EKF") for PrimeStore® MTM sample collection devices. Adam Reynolds is also a Director of EKF and this order has been treated as a related party transaction. Product pricing for the agreement has been prepared on an arm's-length basis and there is no minimum volume requirement. Having consulted with SPARK Advisory Partners Limited, the Independent Directors (those directors other than Mr Reynolds) consider that the terms of the order are fair and reasonable insofar as Shareholders are concerned. https://www.investegate.co.uk/article.aspx?id=202012020700061867H Recent Trading update: https://www.investegate.co.uk/ekf-diagnostics-hldg--ekf-/rns/trading-update/202101120700063139L/
Read Full Thread
Follow
Reply
16/2/2021
07:38		wan: Melody...the relevant announcement/details - On 11 December 2020 the board of EKF (the “Board”) convened and declared a dividend in specie of shares in Trellus to trustees, to be held on trust for the Company's shareholders (the "Dividend"). EKF’s investment in Trellus comprises 27,999,999 A Shares of £0.0001 each and 1 golden share of £0.0001 (the "Golden Share"). The Golden Share is the voting share in the capital of Trellus and will be retained by the Company. The Company's shareholders on the register as at close of business on 17 December 2020 ("Relevant EKF Shareholders") will receive one A Share (each a "Dividend Share") for every 16.25 ordinary share held in the Company. Relevant EKF Shareholders will become the beneficial owners of their respective Dividend Shares upon completion of the transfer of the Dividend Shares to Broadway Nominees Limited (“Broadway”), at which time an ‘omnibus’ share certificate in respect of the Dividend Shares will be issued and held by Broadway, to be held on trust by it on behalf of the Relevant EKF Shareholders for a period of: 365 days following admission to trading on AIM (or another recognised stock exchange) of the issued share capital of Trellus; or if the issued share capital of Trellus is not admitted to trading on AIM (or another recognised stock exchange) within two years of the date that the Dividend is settled, two years from the date that the Dividend is settled (the “Lock-up Period”). During the Lock-up Period, Relevant EKF Shareholders will not be permitted to transfer the legal or beneficial ownership of their Dividend Shares. Full details - hTTps://www.ekfdiagnostics.com/approval-of-dividend-in-specie-of-investment-in-trellus-health.html
Read Full Thread
Follow
Reply
28/1/2021
14:35		rivaldo: NIce feature today on the expansion in Cardiff: Https://www.insidermedia.com/news/wales/ekf-expands-into-second-manufacturing-facility-in-cardiff "EKF expands into second manufacturing facility in Cardiff 28 Jan 2021 EKF Diagnostics has expanded its production with the introduction of a new manufacturing facility in Cardiff. The expansion is to help the listed business meet demand for PrimeStore MTM, a key component of the Covid-19 testing process. PrimeStore MTM allows Covid-19 samples from swabs to be rapidly inactivated in the collection tube, enabling safe transportation and avoiding contamination while preserving RNA for accurate analysis without the need for refrigeration. The new facility is more than 600 sq. metres, representing a 100 per cent increase in manufacturing space. Up to 36,000 PrimeStore MTM tubes will be produced at Llandough every day, adding to EKF’s existing manufacturing onsite at Penarth and at its three other facilities in Texas and Indiana in the US, and Barleben, Germany. EKF engaged only local contractors during the fitting out process and now finished, the new facility at Llandough will provide work for up to 40 staff, operating three tube filling pump lines and three rooms for sample kit assembly. Already EKF has created over 30 new jobs on the production line and in quality assurance, customer services, purchasing, operations and logistics to meet the demand for PrimeStore MTM. EKF expects to employ more staff as it settles into the new facility. EKF’s continued growth, has created opportunities for many other new employees from a diverse range of Covid-19 impacted industries. The new manufacturing facility will also become a distribution hub for EKF’s latest portfolio addition, Covid-SeroKlir which is an antibody test developed by Kantaro Biosciences based on technology from Mount Sinai Health System in New York. EKF chief executive Julian Baines said: "We are proud to be bucking the current employment trend in Wales by taking this strategic decision to increase the size of our manufacturing facilities in Cardiff. We could have stayed in our previous manufacturing space but by moving into larger facilities we have room for growth and can ensure our growing staff numbers can operate in a safe and secure environment." He added: "Although Covid-19 vaccines are being rolled out, we are still experiencing strong demand from both public and private sector customers for PrimeStore MTM. "We are also about to launch our new Covid-19 antibody testing kit which we believe will also be of interest to labs, hospitals and businesses who want to identify which members of staff have antibodies. Those with a high antibody count will have strong resistance to the virus and with regular monitoring can return to the workplace."
Read Full Thread
Follow
Reply
22/1/2021
06:04		wan: Testing, testing, testing! The attributes of PrimeStore appears to be coming evermore to the fore, not to mention EKF's excellent customer service - 21st January 2021 EKF opens larger facility to increase production of key component for COVID-19 testing regime EKF’s new facilities in Llandough, Cardiff, for manufacture of PrimeStore® MTM viral transport media, enabling pathogenic samples to be collected and transported safely and easily in compliance with UN3373 packaging regulations. EKF Diagnostics, the global in vitro diagnostics company, announces that it has expanded into new larger manufacturing facilities at Llandough Trading Estate, Cardiff, to increase production of PrimeStore® MTM viral transport media, a key component for the COVID-19 testing regime. The new facility is over 600 sq. metres, representing a 100% increase in manufacturing area. This enables EKF to fill 36,000 PrimeStore MTM tubes daily and meet growing UK and EU demand for this novel, patented sample collection device successfully evaluated for effective SARS-CoV-2 inactivation by Public Health England [1]. Already an established device for safe and easy transportation of pathogenic samples, millions of PrimeStore MTM tubes have now been sold globally during the SARS-CoV-2 pandemic; and EKF continues to receive escalating numbers of orders from healthcare, education and industry for COVID-19 testing programmes. As well as the additional manufacturing capacity in Wales, EKF has also increased production at its facilities in Barleben, Germany, and USA in Boerne, Texas, and South Bend, Indiana. The new Cardiff facility will also become a distribution hub for EKF’s latest portfolio addition, the Kantaro COVID-SeroKlir SARS-CoV-2 IgG antibody test kit and provide more space for new product development in the laboratories at EKF’s Headquarters in Penarth, Cardiff. In addition to the increased floor space, EKF has grown its workforce at a time when many companies in Wales are sadly being forced to make redundancies. The new facility, fitted out using only local contractors, can accommodate up to 40 staff operating three tube filling pump lines and three rooms for sample kit assembly. Already EKF has created over 30 new jobs, including production line operatives, and in quality assurance, customer services, purchasing, operations and logistics to meet the demand for PrimeStore MTM. EKF expects to employ more staff in the short term as it settles into the new facility. The success of PrimeStore that has necessitated the increased production capacity is due to new high-volume customers, as well as increasing orders from current customers finding that it is helping them to significantly streamline their sample collection and testing processes. This is because the novel sample collection device allows COVID-19 samples from swabs to be rapidly inactivated in the collection tube, avoiding contamination whilst preserving RNA with no requirement for refrigeration. Removing the need for cold chain storage and enabling immediate testing without need for containment in the laboratory delivers cost, efficiency and safety advantages. Leicester University has established an asymptomatic SARS-CoV-2 screening programme to support and reassure staff and students on campus, and reduce viral transmission. “By choosing PrimeStore MTM with its viral inactivation properties, we are ensuring the safe transportation and processing of participants’ samples and ensuring protection for our staff,” said Dr Rebecca Allsopp, Research Associate at Leicester Cancer Research Centre, University of Leicester. “We have the reassurance of RNA stabilisation, protecting sample integrity at room temperature without the need for additional storage requirements. EKF has also provided excellent customer service.” PrimeStore MTM (Molecular Transport Medium) was specifically designed and optimized for molecular testing allowing pathogenic samples to be collected, transported, and processed safely and efficiently. The molecular transport medium inactivates infectious biological pathogens including viruses (such as SARS-CoV-2 and flu A & B), and gram-positive/negative bacteria whilst preserving and stabilizing labile DNA and RNA for downstream molecular applications under standard laboratory conditions. Full release - hTTps://www.ekfdiagnostics.com/ekf-opens-larger-facility-to-increase-production-of-key-component-for-covid-19-testing-regime.html I also very much like that the expansion will free up and enable new product development in the laboratories at EKF’s Headquarters in Penarth, Cardiff.
Read Full Thread
Follow
Reply
23/12/2020
07:55		btgman: Exactly Wan testing testing and more testing is what is on the way this is currently being missed within EKF share price. On top of this EKF's basket of other products is staggering I have said before 2021 will be a more profitable year than 2020 AIMHO GLA BTG
Read Full Thread
Follow
Reply
14/12/2020
07:31		masurenguy: 14 December 2020: Approval of dividend in specie of investment in Trellus Health "Approval by shareholders was granted at the General Meeting held on 10 December 2020, to distribute the Company's entire holding of A Ordinary Shares in Trellus ("A Shares") by way of a dividend in specie to EKF Shareholders on the register at 17 December 2020. The Company's shareholders on the register as at close of business on 17 December 2020 ("Relevant EKF Shareholders") will receive one A Share (each a "Dividend Share") for every 16.25 ordinary share held in the Company. Relevant EKF Shareholders will become the beneficial owners of their respective Dividend Shares upon completion of the transfer of the Dividend Shares to Broadway Nominees Limited ("Broadway"), at which time an 'omnibus' share certificate in respect of the Dividend Shares will be issued and held by Broadway, to be held on trust by it on behalf of the Relevant EKF Shareholders for a period of: -- 365 days following admission to trading on AIM (or another recognised stock exchange) of the issued share capital of Trellus; or -- if the issued share capital of Trellus is not admitted to trading on AIM (or another recognised stock exchange) within two years of the date that the Dividend is settled, two years from the date that the Dividend is settled (the "Lock-up Period"). During the Lock-up Period, Relevant EKF Shareholders will not be permitted to transfer the legal or beneficial ownership of their Dividend Shares. Relevant EKF Shareholders will receive a letter informing them of their beneficial holdings of Dividend Shares shortly after the transfer of the Dividend Shares to Broadway. Following the Lock-up Period, Relevant EKF Shareholders will receive individual certificates in respect of their Dividend Shares.
Read Full Thread
Follow
Reply
08/12/2020
07:34		wan: One assumes that the commencement of mass-manufacturing in the US has now resulted in availability and roll-out here too - EKF introduces accurate quantitative COVID-19 antibody test kit Cardiff, UK – 7 December 2020 – EKF Diagnostics, the global in vitro diagnostics company, announces that it has introduced one of the first tests to precisely measure levels of COVID-19 neutralizing antibodies in individuals. Unlike other antibody tests, the Kantaro COVID-SeroKlir SARS-CoV-2 IgG antibody test kit determines both the presence and specific quantities of human IgG antibodies to the SARS-CoV-2 virus. This enables a broad range of COVID-19 applications, such as delivering vital knowledge for advancing the understanding of protective immunity, assessing vaccine response and accelerating therapeutic treatments. The high performance quantitative COVID-SeroKlir kit has received FDA Emergency Use Authorization (EUA) and is CE marked. It has demonstrated 98.8% sensitivity and 99.6% specificity for detecting SARS-CoV-2 specific IgG antibodies against two SARS-CoV-2 virus antigens, the full-length spike protein and its receptor-binding domain (RBD). This confirmed accuracy means false positives and false negatives are minimized. The best-in-class serologic COVID-19 assay is based on technology developed by clinicians at the Icahn School of Medicine at Mount Sinai Health System in New York in partnership with RenalytixAI, a spinout company from EKF Diagnostics. Here, COVID-SeroKlir has been validated on a highly diverse cohort of more than 75,000 patients, including over 30,000 who were diagnosed with COVID-19; this is more than any other COVID-19 test. In addition, the test has been independently verified by peer reviewed journals, including Nature and Science [1, 2], as well as the U.S. National Institutes of Health (NIH). The Mount Sinai study also demonstrated that over 90% of infected individuals with mild-to-moderate COVID-19 experience robust IgG antibody responses against the viral spike protein [2]. In addition, these COVID-19 neutralizing antibody levels were confirmed to be relatively stable during the first five months after infection. Explaining the value of knowing the precise levels of SARS-CoV-2 IgG antibodies, Julian Baines, CEO of EKF, said, “Quantitative IgG antibody testing can provide important support for determining public health strategies, informing healthcare decision making, and verifying the effectiveness of vaccines as they become available. It is also an essential component of a general health check to determine past COVID-19 infections. This is because COVID-19 has been linked with an increased risk of potentially life-threatening complications, including lung, kidney, and cardiovascular disease.” EKF holds exclusive rights to market and distribute the Kantaro COVID-SeroKlir kit in the UK and Germany, and non-exclusive rights in the rest of Europe. Julian Baines added, “With the capacity to manufacture up to 10 million tests per month, EKF is well placed to drive rapid availability of COVID-SeroKlir kits to a broad range of laboratories for immediate operation without needing specialized testing equipment.” Full release - hTTps://www.ekfdiagnostics.com/ekf-introduces-accurate-quantitative-covid-19-antibody-test-kit.html
Read Full Thread
Follow
Reply
25/11/2020
17:24		james188: The FDA EUA announcement today is clearly positive news, but we do not know how much of the product that Bio-Techne manufactures is going to be allocated to the UK/European markets and so available for marketing and distribution (and so revenue generation) by EKF. We also do not know the commercial deal under the agreement between EKF and Kantaro. My assumption is that most of the kits now being produced will be targeted at the US market. As far as I am aware, Bio-Techne are the sole manufacturer of the test kits. If the Kantaro/EKF marketing and distribution agreement generates material revenues for EKF, it will issue an RNS, sooner or later. So, I can see why the Renalytix share price spiked today (after being subdued), but also why it had no immediate impact on the EKF share price, given its relatively small holding in Renalytix. Some of the other developments hold more immediate promise, in my view, PrimeStore products being an obvious example.
Read Full Thread
Follow
Reply
Ekf Diagnostics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210306 08:16:25